Human Skin-Derived Stem Cells as a Novel Cell Source for In Vitro Hepatotoxicity Screening of Pharmaceuticals

Innovation for hepatotoxicity in vitro research models: A review

“…iPSCs and stem‐cell‐derived hepatocytes, such as human embryonic stem‐cell‐derived (ESCs), human skin‐derived precursors (hSKPs) and human fetal hepatic progenitor cells (hFHPCs) are emerging as important potential sources of unlimited numbers of hepatocytes (Guguen‐Guillouzo, Corlu, & Guillouzo, ; Kim et al, ; Rodrigues et al, ; Si‐Tayeb et al, ; Takahashi et al, ; Zhang et al, ).…”

“…hSKPs and hFHPCs can efficiently differentiate into HLCs in vitro. hSKP/HLCs and hFHPCs/HLCs acquire highly differentiated hepatic functions, and can express hepatic progenitor cell markers and adult hepatocyte marker gene expression, such as albumin, as well as key biotransformation enzymes and influx and efflux drug transporters (Rodrigues et al, ; Zhang et al, ).…”

“…ESCs/HLCs can investigate the hepatotoxicity of drugs, such as acetaminophen and thiazolidinediones, and predict the hepatotoxicity of Chinese herbal medicines and show their toxicity patterns (Duan et al, ; Kim et al, ). Rodrigues et al investigated the steatosis‐inducing effects of sodium valproate using hSKP/HPCs (Rodrigues et al, ). Exposure of hSKPs/HPCs to sub‐cytotoxic concentrations of this reference steatogenic compound showed increased intracellular accumulation of lipid droplets and the modulation of key factors involved in lipid metabolism (Rodrigues et al, ).…”

Concise Review: Human Dermis as an Autologous Source of Stem Cells for Tissue Engineering and Regenerative Medicine

“…Various groups have performed extensive work focusing on isolation, characterization, and in vitro propagation of DSCs [2–6]. Excitingly, it has been demonstrated that DSCs have potential to differentiate not only along mesenchymal lineages [2–6] but also along the ectodermal [4, 7] and endodermal lineages [8]. Differentiation toward these lineages, however, has been shown mostly at the individual cell level or, at most, on small clusters of cells.…”

Human stem cell-derived hepatocytes: breakthrough of an expedient tool for preclinical assessment of drug-induced liver injury?

“…Due to their scarcity, primary R. M. Rodrigues · J. De Kock (*) Department of In Vitro Toxicology and Dermato-Cosmetology, Center for Pharmaceutical Research, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium e-mail: jdekock@vub.ac.be pharmaceutical compounds using a combination of human stem cell-derived hepatocyte-like cells and omics technology are now a fact (Rodrigues et al 2013;Medine et al 2013). Toxic responses equivalent to those observed in primary human hepatocytes have been reported.…”